First coronavirus vaccine trials begin in humans

Tuesday, 17 Mar, 2020

Funded by the U.S. National Institutes of Health and conducted at the Kaiser Permanente Washington Health Research Institute in Seattle, a team of scientists plans to administer varying doses of a vaccine developed by the NIH and Moderna Inc.to 45 young, healthy volunteers, the Associated Press reported.

A US-based company, Inovio Pharmaceuticals aim to begin safety tests for its vaccine candidate in April which will include a few dozen volunteers at the University of Pennsylvania as well as a testing centre in Kansas City, Missouri.

US researchers gave the first shot to the first person in a test of an experimental coronavirus vaccine Monday - leading off a worldwide hunt for protection even as the pandemic surges.

The National Institutes of Health is funding the trial, which is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle.

The expectation is that the vaccine will take roughly 18 months to fully validate in a lab setting.

In a March 16 statement, he said that finding a safe and effective vaccine to block the SARS-CoV-2 virus, which started in China in 2019, "is an urgent health priority".

The vaccine is called mRNA-1273 and was developed by US National Institutes of Health (NIH) scientists and collaborators at biotechnology company Moderna, which is based in Cambridge, Massachusetts.

In the world of biological science, it has become a race as to who will be the first to create the coronavirus vaccine as the amount of Covid-19 cases continues to increase worldwide!

Pharmacist Michael Witte opens a package of the potential vaccine for the COVID-19 coronavirus. More than 50 people have died in the United States and around 3,000 confirmed cases across the 49 states and the District of Columbia. Amalie, 10, and Rebekka, 8, sent a joint question asking: "Dear prime minister, what do you do to strengthen your immune system?"

President Donald Trump has been pushing for swift action on a vaccine, saying in recent days that the work is "moving along very quickly".

Since its outbreak in China in December, the virus has killed about 5,000 persons, with at least 138,000 infected across more than 100 countries. The latter is also being tested in the U.S.by the University of Nebraska Medical Center.

The new coronavirus can cause a mild to severe respiratory illness and symptoms of fever, cough, and shortness of breath.

CureVac said last week they are working on with a multitude of coronavirus vaccine candidates and are selecting the two best to go into clinical trials.